[Autoantibodies to vasoactive peptides and angiotensin converting enzyme in patients with systemic diseases of the connective tissue].
OBJECTIVE
To estimate the level of natural autoantibodies (NAAb) to angiotensin-converting enzyme (ACE) and endogenic mediators affecting vascular tone (bradykinin--BK, angiotensin II--AII, vasopressin--VP) as well as the activity of serum ACE in patients with systemic diseases of the connective tissue.


METHODS
Levels of NAAb were measured by enzyme immunoassay in sera from 30 patients with SLE, 19 patients with rheumatoid arthritis (RA) and 36 patients with scleroderma systematica (SS). Serum from donors served control. IgM NAAb to ACE were measured by a new technique. Serum ACE activity was determined by the initial velocity of hydrolysis reaction using spectrofluometry.


RESULTS
IgM NAAb were detected in the sera of both patients and donors. SS patients had the level of NAAb to ACE in diffuse form significantly higher than in limited (p < 0.05). In SLE and SS patients ACE activity was significantly lower (p < 0.05) than in healthy subjects and RA patients. Levels of NAAb to BK was significantly elevated (p < 0.01) in patients with SLE and RA vs donors while to AII in SS patients it was lowered (p < 0.001). Patients with diffuse SS had NAAb to BK higher than patients with SS limited form (p < 0.01). In SLE the lowest levels of NAAb to all the mediators studied were observed in patients with nephritis, for NAAb to VP the differences were significant (p < 0.05). In patients with urinary syndrome concentration of NAAb to BK was significantly higher (p < 0.01), differences between their levels in patients with nephritis and urinary syndrome were also significant (p < 0.05).


CONCLUSIONS
Further studies are needed for specification of physiological or pathological role of NAAb to endogenic mediators.
Stanislav
M L
ML
Balabanova
R M
RM
Alekperov
R T
RT
Miagkova
M A
MA
Abramenko
T V
TV
Kiselev
I P
IP
Kost
O A
OA
Nikol'skaia
I I
II
Garats
E V
EV
D000804:Angiotensin II / Q000276:immunology*; D001172:Arthritis, Rheumatoid / Q000276:immunology*; D001323:Autoantibodies / Q000032:analysis*; D001782:Blood Donors; D001920:Bradykinin / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007075:Immunoglobulin M / Q000032:analysis; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D007703:Peptidyl-Dipeptidase A / Q000276:immunology*; D012595:Scleroderma, Systemic / Q000276:immunology*; D013050:Spectrometry, Fluorescence; D014667:Vasopressins / Q000276:immunology*
D001323:Autoantibodies; D007075:Immunoglobulin M; D014667:Vasopressins; D000804:Angiotensin II; D007703:Peptidyl-Dipeptidase A; D001920:Bradykinin
Autoantitela k vazoaktivnym peptidam in angiotenzinprevrashchaiushchemu fermentu u bol'nykh s sistemnymi zabolevaniiami soedinitel'noĭ tkani.